Fosamax and Osteonecrosis of the Jaw: Understanding the Biological Plausibility

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specific Risk: The Legacy of Health Information

The domain of general health and science information has long emphasized broad preventive measures and public awareness, focusing on lifestyle factors, nutrition, and common disease prevention. This foundation provides a baseline for understanding how systemic health influences individual well-being. Within this context, the dissemination of scientific knowledge has empowered populations to make informed decisions about their health, often through accessible channels that prioritize clarity and relevance. As this heritage evolves, a natural pivot occurs toward more specialized exposures that arise in occupational and industrial settings. The transition from general health guidance to specific risk assessment becomes necessary when considering substances or treatments that may have unintended consequences in certain populations. For instance, the widespread use of pharmaceuticals in mass production environments introduces a layer of complexity, where workers or consumers may encounter compounds with latent effects not immediately apparent in general health discourse. This shift demands a refined focus on exposure pathways, duration, and cumulative impact, moving beyond broad recommendations to address the nuanced interplay between therapeutic agents and biological systems.

Bridging to Bisphosphonates: The Case of Fosamax

The bridge concept emerges: from a legacy of universal health literacy to a targeted examination of how specific exposures, such as those involving bisphosphonates, can alter risk profiles in occupational contexts, without yet delving into mechanistic specifics. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption by osteoclasts, which reduces bone turnover. While this effect is beneficial for increasing bone mass and reducing fracture risk, it also underlies the biological plausibility of a serious adverse effect: osteonecrosis of the jaw (ONJ).

Biological Plausibility of Fosamax-Related Osteonecrosis of the Jaw

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, and exposed bone that fails to heal after dental procedures. Diagnosis is based on clinical examination and imaging, with the hallmark being persistent bone exposure for more than eight weeks in the absence of radiation therapy to the jaw. The biological plausibility linking Fosamax to ONJ is grounded in the drug's pharmacology and the unique physiology of the jawbone. Bisphosphonates like alendronate accumulate in bone tissue, particularly at sites of high bone turnover. The jawbone undergoes constant remodeling due to mechanical stress from chewing and the presence of teeth, making it a site of relatively high bone turnover. By suppressing osteoclast activity, Fosamax reduces the ability of the jawbone to remodel and repair microdamage. This suppression of bone turnover can lead to a state where the bone becomes brittle and less able to heal after minor trauma, such as tooth extraction. Additionally, the anti-angiogenic properties of bisphosphonates may impair blood supply to the jawbone, further contributing to necrosis. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights that the jawbone's unique structural and mechanical properties make it particularly susceptible to the effects of bisphosphonate therapy.

Risk Factors and Clinical Evidence

Risk factors for developing ONJ while taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and documented harm from ONJ is variable. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in clinical trials was low and not statistically different from placebo, likely due to the rarity of the condition and the exclusion of high-risk patients from trials.

Causation Considerations and Warnings

Regarding adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under 'Warnings and Precautions' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section describes the association, risk factors, and recommendations for management, including discontinuation of treatment before invasive dental procedures. However, for affected patients, causation considerations are complex. ONJ can occur spontaneously and is associated with multiple risk factors, making it difficult to attribute a specific case solely to Fosamax exposure. The biological plausibility is strong, but individual susceptibility, duration of therapy, and concurrent risk factors all play a role. Patients who develop ONJ while on Fosamax should be evaluated for other contributing factors, and the decision to discontinue bisphosphonate therapy should be made in consultation with a healthcare provider, weighing the risks of fracture from untreated osteoporosis against the risk of ONJ progression. In summary, the evidence supports a biologically plausible link between Fosamax and osteonecrosis of the jaw, mediated by suppression of bone turnover and impaired healing in the jawbone. The risk is increased with longer duration of use and in the presence of dental procedures or other risk factors. Warnings in the prescribing information are present but may not fully capture the variable timeline and multifactorial nature of the condition. For affected patients, a careful assessment of causation and risk management is essential.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the biological mechanism linking Fosamax to osteonecrosis of the jaw?

Fosamax (alendronate) inhibits bone resorption by osteoclasts, reducing bone turnover. The jawbone, due to constant remodeling from chewing and teeth, is a site of high bone turnover. Suppression of osteoclast activity impairs the jawbone's ability to repair microdamage, leading to brittle bone and poor healing after minor trauma like tooth extraction. Additionally, anti-angiogenic effects may reduce blood supply, contributing to necrosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk increases with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ occur?

The time to onset of ONJ symptoms is variable, ranging from one day to several months after starting the drug. Most patients experience relief after stopping Fosamax, but some have recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Are there adequate warnings about ONJ in Fosamax prescribing information?

Yes, the prescribing information includes a specific section on osteonecrosis of the jaw under 'Warnings and Precautions,' describing the association, risk factors, and management recommendations, including discontinuation before invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, causation is complex due to multiple contributing factors.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.